Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib Versus Investigator's Choice in r/r PTCL
NCT07234162Phase 3Recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- May 2024
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of golidocitinib in peripheral T-cell lymphoma (PTCL), sponsored by Dizal Pharmaceutical Co., Ltd.. Started May 2024; status: recruiting.
02
Drugs
golidocitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07234162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07234162.